Post-Traumatic Stress Disorder (PTSD): Opportunity Analysis and Forecasts to 2028
Post-Traumatic Stress Disorder (PTSD): Opportunity Analysis and Forecasts to 2028
Summary
Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder that can occur in people who have experienced or witnessed a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, rape, or other violent personal assault. Symptoms include “re-experiencing” distressing memories, hypervigilance, avoidant behaviors, sweating, tremors, and dissociation.
The total Post-Traumatic Stress Disorder (PTSD) market was estimated to be worth US$211.4m across the seven major markets (7MM - US, France, Germany, Italy, Spain, UK and Japan) in 2018. This is expected to grow at a compound annual growth rate (CAGR) of 18.7% to reach US$1.2bn by 2028. Lack of efficacy is the most pressing unmet need in the Post-Traumatic Stress Disorder (PTSD) market and there have been no approved products to treat the disorder since 2001.
However, two drug candidates in the Post-Traumatic Stress Disorder (PTSD) pipeline that are expected to launch in the seven major markets (7MM - US, France, Germany, Italy, Spain, UK and Japan) by 2022 are set to revolutionize the treatment of the disorder, as evidenced by promising results in clinical trials. Zoloft and Paxil, currently the only two approved products in the seven major markets (7MM - US, France, Germany, Italy, Spain, UK and Japan) for Post-Traumatic Stress Disorder (PTSD), are antidepressants of the selective-serotonin reuptake inhibitors (SSRIs) class. The fact that Zoloft and Paxil work via the same mechanism of action means that they have the same unpleasant side effects as well as boxed warnings for impulsiveness and suicidal behaviors.
Brexpiprazole, an atypical antipsychotic approved for the treatment of major depressive disorder and schizophrenia, is in the pipeline for Post-Traumatic Stress Disorder (PTSD) and has shown efficacy when administered as an adjunct to Zoloft. The well-established safety profile and low frequency of adverse effects puts brexpiprazole in good stead to become the highest selling drug in the market, with forecasted annual sales of US$361.7m by 2028.
MDMA is a stimulant and late-stage pipeline product which was given breakthrough designation by the FDA, despite being a widely abused recreational drug. Its superior efficacy to marketed therapies and low frequency of administration are likely to be viewed favorably by physicians and patients alike. It is expected that in its first year on the market, MDMA is set to acquire a large patient share in the US as the first new drug for chronic Post-Traumatic Stress Disorder (PTSD) to be approved in 18 years. Brexpiprazole and MDMA are set to make up 47% of drug sales in 2022 and this figure will climb to 59% in 2028.
This potential for high sales whilst addressing the longstanding clinical unmet needs for the indication is clear assurance of the increasing efforts to add Post-Traumatic Stress Disorder (PTSD) to the list of psychiatric disorders that will experience market growth in the coming years and beyond.
The report “Post-Traumatic Stress Disorder (PTSD): Opportunity Analysis and Forecasts to 2028” provides an overview of Post-Traumatic Stress Disorder (PTSD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the Post-Traumatic Stress Disorder (PTSD) therapeutics market
Key Questions Answered:
- What were the key Post-Traumatic Stress Disorder (PTSD) treatments in 2018?
- When will the late stage pipeline products launch, and how will it affect drug sales and the overall Post-Traumatic Stress Disorder (PTSD) market in the seven major markets (7MM - US, France, Germany, Italy, Spain, UK and Japan)?
- Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?
- Overview of PTSD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized PTSD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (acute, chronic and delayed-onset) forecast from 2018 to 2028.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PTSD therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PTSD therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global PTSD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global PTSD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PTSD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- 1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
- 2 PTSD: Executive Summary
- 2.1 Double-Digit Growth Expected in PTSD Market from 2018-2028
- 2.2 Focus Is on Label Expansion, Comorbidities, and Novel Mechanisms of Action in PTSD Pipeline
- 2.3 Lack of Efficacious Pharmacotherapeutic Options Is a Major Unmet Need
- 2.4 Brexpiprazole and Midomafetamine to Be Top-Selling Drugs in 2028
- 2.5 What Do Physicians Think?
- 3 Introduction
- 3.1 Catalyst
- 3.2 Related Reports
- 4 Disease Overview
- 4.1 Etiology and Pathophysiology
- 4.1.1 Etiology
- 4.1.2 Pathophysiology
- 4.2 Classification or Staging Systems
- 5 Epidemiology
- 5.1 Disease Background
- 5.2 Risk Factors and Comorbidities
- 5.3 Global and Historical Trends
- 5.4 Forecast Methodology
- 5.4.1 Sources Used
- 5.4.2 Forecast Assumptions and Methods
- 5.5 Epidemiological Forecast for PTSD (2018-2028)
- 5.5.1 12-Month Total Prevalent Cases of PTSD
- 5.5.2 Age-Specific 12-Month Total Prevalent Cases of PTSD
- 5.5.3 Sex-Specific 12-Month Total Prevalent Cases of PTSD
- 5.5.4 12-Month Total Prevalent Cases of PTSD by Onset of Disease
- 5.6 Discussion
- 5.6.1 Epidemiological Forecast Insight
- 5.6.2 Limitations of Analysis
- 5.6.3 Strengths of Analysis
- 6 Current Treatment Options
- 6.1 Overview
- 6.2 Psychotherapy
- 7 Unmet Needs and Opportunity Assessment
- 7.1 Overview
- 7.2 Improved Efficacy of Available Treatments
- 7.3 Improving Side-Effect Profiles and Patient Compliance
- 7.4 Increased Access to Treatment for Vulnerable Populations
- 7.5 Clearer Diagnostic Guidelines
- 8 R&D Strategies
- 8.1 Overview
- 8.1.1 Repurposing Atypical Antipsychotics and Other Marketed Drugs
- 8.1.2 Drug Candidates with Novel Mechanisms of Action
- 8.1.3 Targeting Key Comorbidities of PTSD
- 8.2 Clinical Trials Design
- 8.2.1 The Preference for Straightforward Treatment Regimens
- 8.2.2 The Interplay of Psychotherapeutic and Pharmacotherapeutic Strategies
- 8.2.3 Studying Off-Label Therapeutics to Generate Reliable Clinical Data
- 9 Pipeline Assessment
- 9.1 Overview
- 9.2 Innovative Early-Stage Approaches
- 9.3 Other Drugs in Development
- 10 Pipeline Valuation Analysis
- 10.1 Clinical Benchmark of Key Pipeline Drugs
- 10.2 Commercial Benchmark of Key Pipeline Drugs
- 10.3 Competitive Assessment
- 10.4 Top-Line 10-Year Forecast
- 10.4.1 US
- 10.4.2 5EU
- 10.4.3 Japan
- 11 Appendix
- 11.1 Bibliography
- 11.2 Abbreviations
- 11.3 Methodology
- 11.3.1 Forecasting Methodology
- 11.3.2 Diagnosed Patients
- 11.3.3 Percent Drug-Treated Patients
- 11.3.4 Drugs Included in Each Therapeutic Class
- 11.3.5 Launch and Patent Expiry Dates
- 11.3.6 General Pricing Assumptions
- 11.3.7 Individual Drug Assumptions
- 11.3.8 Generic Erosion
- 11.3.9 Pricing of Pipeline Agents
- 11.4 Primary Research - KOLs Interviewed for This Report
- 11.4.1 KOLs
- 11.5 Primary Research - Prescriber Survey
- 11.6 About the Authors
- 11.6.1 Analyst
- 11.6.2 Therapy Area Director
- 11.6.3 Epidemiologist
- 11.6.4 Reviewers
- 11.6.5 Global Director of Therapy Analysis and Epidemiology
- 11.6.6 Global Head and EVP of Healthcare Operations and Strategy
- 11.7 About GlobalData
- 11.8 Contact Us
- 11.9 Disclaimer
- List of Tables
- Table 1: Post-Traumatic Stress Disorder: Key Metrics in the 7MM
- Table 2: Overview of PTSD symptoms included in DSM-5
- Table 3: Risk Factors and Comorbid Conditions Associated with PTSD
- Table 4: Off-Label Drugs for PTSD in the 7MM
- Table 5: Treatment Guidelines for PTSD
- Table 6: Approved Treatments for PTSD, 2019
- Table 7: Comparison of Therapeutic Classes in Development for PTSD, 2018-2028
- Table 8: Innovative Early-Stage Approaches for PTSD, 2019
- Table 9: Drugs in Development for PTSD, 2019
- Table 10: Clinical Benchmark of Key Pipeline Drugs - PTSD
- Table 11: Commercial Benchmark of Key Pipeline Drugs - PTSD
- Table 12: Key Events Impacting Global Sales for PTSD, 2018-2028
- Table 13: PTSD Market - Global Drivers and Barriers, 2018-2028
- Table 14: Key Historical and Projected Launch Dates for PTSD
- Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
- List of Figures
- Figure 1: Global Sales Forecast by Country for PTSD in 2018 and 2028
- Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Zoloft
- Figure 3: Fight-or-Flight Response Overview and Pathophysiological Aspects of PTSD
- Figure 4: 7MM, 12-Month Total Prevalence of PTSD (%), Men and Women, Ages ≥18 Years, 2018
- Figure 5: 7MM, Sources Used and Not Used to Forecast the 12-Month Total Prevalent Cases of PTSD
- Figure 6: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of PTSD by Onset of Disease
- Figure 7: 7MM, 12-Month Total Prevalent Cases of PTSD, Both Sexes, Ages ≥18 Years, 2018
- Figure 8: 7MM, Age-Specific 12-Month Total Prevalent Cases of PTSD, Both Sexes, Ages ≥18 Years, 2018
- Figure 9: 7MM, Sex-Specific 12-Month Total Prevalent Cases of PTSD, Ages ≥18 Years, 2018
- Figure 10: 7MM, 12-Month Total Prevalent Cases of PTSD by Onset of Disease, Both Sexes, Ages ≥18 Years, 2018
- Figure 11: Unmet Needs and Opportunities in PTSD
- Figure 12: Overview of the Development Pipeline in PTSD
- Figure 13: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for PTSD in the 7MM During the Forecast Period
- Figure 14: Competitive Assessment of the Marketed and Pipeline PTSD Drugs Benchmarked Against the SOC, Zoloft
- Figure 15: Global (7MM) Sales Forecast by Country for PTSD in 2018 and 2028
- Figure 16: Global Sales Forecast by Brand for PTSD in 2018 and 2028
- Figure 17: Sales Forecast by Brand for PTSD in the US in 2018 and 2028
- Figure 18: Sales Forecast by Brand for PTSD in the 5EU Markets in 2018 and 2028
- Figure 19: Sales Forecast by Brand for PTSD in Japan in 2018 and 2028
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook